Literature DB >> 11284691

Ability of the Tat basic domain and VP22 to mediate cell binding, but not membrane translocation of the diphtheria toxin A-fragment.

J Wesche, S Olsnes.   

Abstract

A number of proteins are able to enter cells from the extracellular environment, including protein toxins, growth factors, viral proteins, homeoproteins, and others. Many such translocating proteins, or parts of them, appear to be able to carry with them cargo into the cell, and a basic sequence from the HIV-1 Tat protein has been reported to provide intracellular delivery of several fused proteins. For evaluating the efficiency of translocation to the cytosol, this TAT-peptide was fused to the diphtheria toxin A-fragment (dtA), an extremely potent inhibitor of protein synthesis which normally is delivered efficiently to the cytosol by the toxin B-fragment. The fusion of the TAT-peptide to dtA converted the protein to a heparin-binding protein that bound avidly to the cell surface. However, no cytotoxicity of this protein was detected, indicating that the TAT-peptide is unable to efficiently deliver enzymatically active dtA to the cytosol. Interestingly, the fused TAT-peptide potentiated the binding and cytotoxic effect of the corresponding holotoxin. We made a fusion protein between VP22, another membrane-permeant protein, and dtA, and also in this case we detected association with cells in the absence of a cytotoxic effect. The data indicate that transport of dtA into the cell by the TAT-peptide and VP22 is inefficient.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11284691     DOI: 10.1021/bi002443l

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  13 in total

1.  Might a vanguard of mRNAs prepare cells for the arrival of herpes simplex virus?

Authors:  Thomas Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-25       Impact factor: 11.205

2.  Induction of insolubility by herpes simplex virus VP22 precludes intercellular trafficking of N-terminal Apoptin-VP22 fusion proteins.

Authors:  Saskia A Rutjes; Piter J Bosma; Jennifer L Rohn; Mathieu H M Noteborn; John G Wesseling
Journal:  J Mol Med (Berl)       Date:  2003-07-16       Impact factor: 4.599

Review 3.  Targeting antibodies to the cytoplasm.

Authors:  Andrea L J Marschall; André Frenzel; Thomas Schirrmann; Manuela Schüngel; Stefan Dübel
Journal:  MAbs       Date:  2011-01-01       Impact factor: 5.857

Review 4.  The taming of the cell penetrating domain of the HIV Tat: myths and realities.

Authors:  Ashok Chauhan; Akshay Tikoo; Arvinder K Kapur; Mahavir Singh
Journal:  J Control Release       Date:  2006-11-17       Impact factor: 9.776

Review 5.  Cell penetrating peptides: intracellular pathways and pharmaceutical perspectives.

Authors:  Leena N Patel; Jennica L Zaro; Wei-Chiang Shen
Journal:  Pharm Res       Date:  2007-04-19       Impact factor: 4.200

6.  Cell-penetrating peptide for enhanced delivery of nucleic acids and drugs to ocular tissues including retina and cornea.

Authors:  Leslie N Johnson; Siobhan M Cashman; Rajendra Kumar-Singh
Journal:  Mol Ther       Date:  2007-10-09       Impact factor: 11.454

7.  TAT-mediated intracellular delivery of purine nucleoside phosphorylase corrects its deficiency in mice.

Authors:  Ana Toro; Eyal Grunebaum
Journal:  J Clin Invest       Date:  2006-09-07       Impact factor: 14.808

8.  Protein transduction domains fused to virus receptors improve cellular virus uptake and enhance oncolysis by tumor-specific replicating vectors.

Authors:  Florian Kühnel; Bernd Schulte; Thomas Wirth; Norman Woller; Sonja Schäfers; Lars Zender; Michael Manns; Stefan Kubicka
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

Review 9.  Biological applications of protein transduction technology.

Authors:  Panagiotis S Kabouridis
Journal:  Trends Biotechnol       Date:  2003-11       Impact factor: 19.536

10.  Bovine herpesvirus tegument protein VP22 enhances thymidine kinase/ganciclovir suicide gene therapy for neuroblastomas compared to herpes simplex virus VP22.

Authors:  Zhaohua Qiu; Jerome S Harms; Jun Zhu; Gary A Splitter
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.